BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 11994118)

  • 1. Somatostatins and their role in thyroid cancer.
    England RJ; Atkin SL
    Clin Otolaryngol Allied Sci; 2002 Apr; 27(2):120-3. PubMed ID: 11994118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatostatin analogues have no role in the treatment of advanced differentiated thyroid cancer.
    Alhamarneh O; Murphy J; Atkin SL; England RJ
    J Laryngol Otol; 2004 Aug; 118(8):653-4. PubMed ID: 15453947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatostatin analogs in the treatment of medullary thyroid carcinoma.
    Díez JJ; Iglesias P
    J Endocrinol Invest; 2002 Oct; 25(9):773-8. PubMed ID: 12398235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatostatin analogs in acromegaly.
    Freda PU
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3013-8. PubMed ID: 12107192
    [No Abstract]   [Full Text] [Related]  

  • 5. Advances in the use of somatostatins in the management of endocrine tumors.
    Chaudhry A; Kvols L
    Curr Opin Oncol; 1996 Jan; 8(1):44-8. PubMed ID: 8868099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-alpha versus somatostatin or the combination of both in metastatic neuroendocrine gut and pancreatic tumours.
    Faiss S; Scherübl H; Riecken EO; Wiedenmann B
    Digestion; 1996; 57 Suppl 1():84-5. PubMed ID: 8813478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatostatin Analogues in Neuroendocrine Tumors.
    Kulke MH
    J Natl Compr Canc Netw; 2016 Mar; 14(3):241-2. PubMed ID: 26957610
    [No Abstract]   [Full Text] [Related]  

  • 8. The tumour vanishes.
    Todd JF; Meeran K
    Clin Endocrinol (Oxf); 2000 Dec; 53(6):663-4. PubMed ID: 11155085
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review.
    Arnold R; Simon B; Wied M
    Digestion; 2000; 62 Suppl 1():84-91. PubMed ID: 10940693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of somatostatin analogues in the treatment of neuroendocrine tumours based on the results of recent clinical trials].
    Igaz P
    Orv Hetil; 2014 Nov; 155(48):1908-12. PubMed ID: 25417137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Established clinical use of octreotide and lanreotide in oncology.
    Oberg K
    Chemotherapy; 2001; 47 Suppl 2():40-53. PubMed ID: 11275701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carcinoid of the pancreas.
    Migliori M; Tomassetti P; Lalli S; Casadei R; Santini D; Corinaldesi R; Gullo L
    Pancreatology; 2002; 2(2):163-6. PubMed ID: 12123097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review.
    Chan DL; Ferone D; Albertelli M; Pavlakis N; Segelov E; Singh S
    Endocrine; 2017 Sep; 57(3):366-375. PubMed ID: 28726183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Commentary: Somatostatin analogs-How we choose, and why.
    Reidy-Lagunes D; Raj N; Saltz L
    Semin Oncol; 2017 Apr; 44(2):157-158. PubMed ID: 28923214
    [No Abstract]   [Full Text] [Related]  

  • 15. [Somatostatin analogs in the treatment of pancreatic cancer: utopia or feasible alternative?].
    Zalatnai A; Pogány V
    Orv Hetil; 2000 Oct; 141(43):2333-8. PubMed ID: 11089387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of type II gastric carcinoid tumors with somatostatin analogues.
    Tomassetti P; Migliori M; Caletti GC; Fusaroli P; Corinaldesi R; Gullo L
    N Engl J Med; 2000 Aug; 343(8):551-4. PubMed ID: 10954763
    [No Abstract]   [Full Text] [Related]  

  • 17. Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid.
    Raderer M; Kurtaran A; Scheithauer W; Fiebiger W; Weinlaender G; Oberhuber G
    Oncology; 2001; 60(2):141-5. PubMed ID: 11244329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly.
    Amato G; Mazziotti G; Rotondi M; Iorio S; Doga M; Sorvillo F; Manganella G; Di Salle F; Giustina A; Carella C
    Clin Endocrinol (Oxf); 2002 Jan; 56(1):65-71. PubMed ID: 11849248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors.
    Pokuri VK; Fong MK; Iyer R
    Curr Oncol Rep; 2016 Jan; 18(1):7. PubMed ID: 26743514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of somatostatin analogs in the management of medullary thyroid carcinoma.
    Lupoli GA; Fonderico F; Fittipaldi MR; Colarusso S; Panico A; Cavallo A; Di Micco L; Lupoli G
    J Endocrinol Invest; 2003; 26(8 Suppl):72-4. PubMed ID: 15233217
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.